Incyte Corporation vs Macy's Inc — how do they compare? Incyte Corporation trades at $120.67 (market cap $24.54B), while Macy's Inc trades at $23.79 (market cap $6.45B). The key difference: Incyte Corporation is far larger — about 3.8× Macy's Inc's market cap, and Macy's Inc pays a 3.12% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | M | |
|---|---|---|
Market Cap | $24.54B | $6.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $26.21 |
52-Week Low | $81.61 | $12.73 |
Enterprise Value | $20.04B | $10.26B |
Dividend Yield | — | 3.12% |
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Macy's stock trades at $23.78, down 4.5% over 24 hours, with technical indicators showing a bullish moving average signal but neutral oscillators. The company demonstrates improving fundamentals with three consecutive quarterly earnings beats and positive cash flow trends. Recent institutional buying and analyst coverage reflect cautious optimism amid the company's turnaround efforts.
The stock presents value investment potential with attractive valuation multiples (P/E 10.13, P/S 0.3) and improving profitability. Key risks include retail sector headwinds and execution of the 'Bold New Chapter' strategy. The consensus price target of $24.83 suggests modest upside potential from current levels.
Trailing returns across standard periods
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →